Sources Mirena (hormonal IUD) Mayo Clinic. 5 Sep
doi: 10.1161/ATVBAHA.109.201533
NICE prioritises SGLT2 inhibitors for people with established or high risk of cardiovascular or kidney disease, with GLP-1 receptor agonists considered in specific scenarios, particularly when weight loss is desired
Society Guidelines and Scientific Statements Speiser PW, Rudolf MCJ, Anhalt H, Camacho-Hubner C, Chiarelli F, Eliakim A, Freemark M, Gruters G, Hershkovitz E, Iughetti L, Krude H, Latzer Y, Lustig RH, Pescovitz OH, Pinhas-Hamiel O, Rogol AD, Shalitin S, Sultan C, Stein D, Vardi P, Werther GA, Zadik Z, Zuckerman-Levin N, Hochberg Z: Consensus development: childhood obesity
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has received significant attention for its weight-loss benefits and therapeutic potential in diabetes management
Because tirzepatide slows down gastric emptyingthe rate at which food and medicine leave your stomachit can change how your body absorbs oral medications
